Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

Pages

13 results
6:57 AM, Mar 08, 2017  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast cancer Zebrafish studies suggest inhibiting TGFβ1 or LFA-1 could help treat metastatic breast cancer …
tissue. In two xenograft zebrafish models of metastatic breast cancer, antibodies against human TGFβ1 or LFA-1
metastasis compared with an isotype-matched control antibody. Next steps could include testing the anti-TGFβ1 and anti-LFA-1
12:00 AM, Feb 25, 2016  |  BC Innovations | Product R&D

Ironwood's brainy idea

τ References  Zenaro, E., et al. "Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1
12:00 AM, Aug 13, 2015  |  BC Innovations | Distillery Therapeutics

Therapeutics: LFA-1 (CD11a-CD18)

disease (AD) Mouse studies suggest temporary depletion of neutrophils or inhibition of the neutrophil-trafficking protein LFA-1
In a transgenic mouse model of AD, systemic depletion of neutrophils or treatment with an anti-LFA-1
respectively. Next steps include investigating other undisclosed leukocyte proteins that contribute to AD pathology. TARGET/MARKER/PATHWAY: LFA-1
12:00 AM, Apr 16, 2015  |  BC Innovations | Product R&D

Antagonizing psoriasis

antifolates and retinoids. Inflammatory receptors (Infl. receptors) include: CD4, CD6 , CD28, CD58 (LFA-3) , LFA-1
12:00 AM, Apr 12, 2012  |  BC Innovations | Targets & Mechanisms

DEL1: taking the bite out of periodontitis

blocks interactions between intercellular adhesion molecule-1 ( Icam-1 ; Cd54 ) on endothelial cells and Lfa-1 ( Cd11a-Cd18
damage and tooth loss. Lastly, the team showed that local administration of antagonists of IL-17, LFA-1
recruits [c] circulating neutrophils to the site of inflammation. At the endothelia of blood vessels, LFA-1
12:00 AM, Nov 03, 2011  |  BC Innovations | Distillery Therapeutics

Indication: Autoimmune disease

status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Integrin aL (CD11A); integrin b2 (LFA-1
12:00 AM, Nov 03, 2011  |  BC Innovations | Distillery Therapeutics

Indication: Autoimmune disease

Anderson Cancer Center, Houston, Texas e-mail: cdong@mdanderson.org Multiple sclerosis (MS) Integrin aL (CD11A); integrin b2 (LFA-1
12:00 AM, May 05, 2011  |  BC Innovations | Distillery Therapeutics

Indication: Inflammation

Licensing status Publication and contact information Inflammation Inflammation Growth differentiation factor 15 (GDF15); integrin b2 (LFA-1
12:00 AM, Mar 24, 2011  |  BC Innovations | Distillery Techniques

Technology: Drug platforms

treatment with three antibodies against CTLA-4 (CD152), CD40 ligand (CD40LG; CD40L; CD154) and integrin b2 (LFA-1
12:00 AM, Apr 01, 2010  |  BC Innovations | Distillery Techniques

Technology: Drug platforms

and diagnostics. As proof of principle, single-chain antibodies against the active domain of integrin b2 (LFA-1

Pages